Evaluate the effect of ofatumumab on serum immunoglobulin (Ig) levels ≤5 years during the core phase 3 ASCLEPIOS I/II (NCT02792218/NCT02792231) and on-going open-label ALITHIOS (NCT03650114) extension studies.
No takes yet. Share an insight, caveat, or question.
Bar‐Or et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: